Lymph directing prodrugs
US-2024050573-A1 · Feb 15, 2024 · US
Methods and compositions for treating infection
US10004701B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10004701-B2 |
| Application number | US-201615356940-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 21, 2016 |
| Priority date | Sep 27, 2012 |
| Publication date | Jun 26, 2018 |
| Grant date | Jun 26, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein are compositions and methods for treating or preventing infection.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating an enterococcal infection in a subject with an enterococcal infection, the method comprising administering to the subject an effective amount of a compound of Formula III or a pharmaceutically acceptable salt thereof, wherein R 1 and R 2 are independently selected from ethyl or methyl, n is 1 or 2, R 3 and R 4 are both phenyl or substituted phenyl, wherein the substituent can be halo, hydroxyl, a lower alkyl or a substituted lower alkyl wherein the substituent can be halo, hydroxy, or lower alkoxy, and R 5 is hydrogen, a halogen, a lower alkyl from about 1 to 4 carbon atoms or a substituted alkyl wherein the substituent can be halo, hydroxy, or lower alkoxy. 2. The method of claim 1 , wherein the enterococcal infection is a respiratory infection. 3. The method of claim 1 , wherein the enterococcal infection is a gastrointestinal infection. 4. The method of claim 1 , wherein the enterococcal infection is a skin infection. 5. The method of claim 1 , wherein the enterococcal infection is an Enterococcus faecium infection. 6. The method of claim 1 , wherein the enterococcal infection is a small colony variant bacterial infection. 7. The method of claim 1 , wherein the compound is selected from the group consisting of clomiphene or a pharmaceutically acceptable salt thereof; tamoxifen or a pharmaceutically acceptable salt thereof; and 4-hydroxy tamoxifen or a pharmaceutically acceptable salt thereof.
Assignees
Inventors
Classifications
Antimycotics · CPC title
Antivirals · CPC title
Antibacterial agents · CPC title
Phosphorus compounds · CPC title
having an oxo group in position 17, e.g. estrone · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10004701B2 cover?
- Provided herein are compositions and methods for treating or preventing infection.
- Who is the assignee on this patent?
- Univ Rochester, Univ Kansas
- What technology area does this patent fall under?
- Primary CPC classification A61K31/138. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 26 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).